Immunohistochemistry is generally sufficient for diagnosis, although FISH or sequencing can be performed to demonstrate biallelic (homozygous) deletions of the SMARCB1 gene [59] or loss-of-function (mostly truncating) mutations in SMARCA4-deficient carcinomas [63]. This evidence concerns the gene SMARCB1 and carcinoma.